Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Companyâs operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
äŒæ¥ã³ãŒãTCRT
äŒç€ŸåAlaunos Therapeutics Inc
äžå Žæ¥Aug 20, 2004
æé«çµå¶è²¬ä»»è
ãCEOãWeis (Holger)
åŸæ¥å¡æ°1
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 20
æ¬ç€Ÿæåšå°501 E Las Olas Blvd
éœåžFORT LAUDERDALE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·33301
é»è©±çªå·13463554099
ãŠã§ããµã€ãhttps://alaunos.com/
äŒæ¥ã³ãŒãTCRT
äžå Žæ¥Aug 20, 2004
æé«çµå¶è²¬ä»»è
ãCEOãWeis (Holger)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã